Market Place
Sourcing Support
Lyndra Announces Positive Data from Phase 3 Study with Oral Weekly Risperidone
04 Jan 2024 //
BUSINESSWIRE
Sun Pharma to acquire 16.7% stake in Lyndra Therapeutics for $30 mn
02 Jan 2024 //
INDIAN PHARMA POST
Lyndra Therapeutics raises US$101 million in Series E funding
25 Dec 2023 //
INDIAN PHARMA POST
Lyndra Therapeutics Raises $101 Million in Series E Funding
21 Dec 2023 //
BUSINESSWIRE
Lyndra lays off 23% of workers
15 Sep 2023 //
ENDPTS
Lyndra Announces Leadership Changes, Update on Pivotal Trial Progress
17 Jul 2023 //
BUSINESSWIRE
Lyndra eyes $180M Series D for potential 2026 launch of schizophrenia med
09 Jun 2023 //
ENDPTS
Lyndra Therapeutics Presents Data on Long-Acting Oral Weekly Risperidone
31 May 2023 //
BUSINESSWIRE
Lyndra Doses 1st Trial Participant in Pivotal Study of Oral Weekly Risperidone
09 May 2023 //
BUSINESSWIRE
Lyndra Therapeutics Announces New Board Members and Chief Technology Officer
05 Jan 2023 //
BUSINESSWIRE
Lyndra’ LYNX™ Drug Delivery Platform Wins Fierce Life Sciences Innovation Award
15 Nov 2022 //
BUSINESSWIRE
Lyndra`s President and CPO J. Ballinger Named to NSBA Leadership Council
16 Jun 2022 //
BUSINESSWIRE
Lyndra Begins Dosing in Study of Oral Biweekly Ivermectin (LYN-163)
09 Jun 2022 //
BUSINESSWIRE
Lyndra Therapeutics Appoints Klas Holmlund as CFO
08 Dec 2021 //
BIOSPACE
Lyndra Therapeutics Advances Leadership in Key Roles
20 Sep 2021 //
BUSINESSWIRE
Lyndra’s Investigational Oral, Weekly Opioid Use Disorder Treatment LYN-014
27 Jul 2021 //
PR NEWSWIRE
Lyndra Announces Positive Outcome of End-of-Phase 2 Meeting with FDA on LYN-005
19 Jul 2021 //
BUSINESSWIRE
Lyndra raises $60.5M in bid to replace existing HIV
26 Jun 2021 //
ENDPTS
Lyndra Therapeutics Completes $60.5 Million Series C Financing
26 Jun 2021 //
BUSINESSWIRE
Lyndra Therapeutics Presents Data on Once-Weekly Oral Buprenorphine Treatment
26 Jun 2021 //
BUSINESSWIRE
Lyndra banks $61M to bring long-acting pill into pivotal trial
24 Jun 2021 //
FIERCEBIOTECH
Lyndra Receives FDA Clearance of i New Drug Application for LYN-014
06 May 2021 //
BUSINESSWIRE
Lyndra Therapeutics Receives FDA Clearance of INDA for LYN-014
06 May 2021 //
BUSINESSWIRE
Lyndra Presents Promising Phase 2 Data on Once-Weekly Oral Risperidone
19 Apr 2021 //
BIOSPACE
Lyndra Therapeutics Announces First Subjects Dosed in Phase 1 Clinical Trial
21 Jan 2021 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.